Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.78 USD | +4.25% | +12.17% | +60.47% |
04-23 | Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU | MT |
04-22 | RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk | MT |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Equities
- EWTX Stock
- Revisions Edgewise Therapeutics, Inc.